Drug Approval | December 20, 2021
WHO grants EUL for Covovax
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Acute therapies continue to report strong growth compared to chronic ones.
Filing marks first protein-based vaccine submitted to MHRA for authorization
It is a recombinant nanoparticle protein-based vaccine
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Subscribe To Our Newsletter & Stay Updated
